PRAH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRAH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PRA Health Sciences's enterprise value is $11,473 Mil. PRA Health Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 was $3,333 Mil. Therefore, PRA Health Sciences's EV-to-Revenue for today is 3.44.
The historical rank and industry rank for PRA Health Sciences's EV-to-Revenue or its related term are showing as below:
During the past 9 years, the highest EV-to-Revenue of PRA Health Sciences was 3.58. The lowest was 1.54. And the median was 2.58.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-13), PRA Health Sciences's stock price is $165.21. PRA Health Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $51.08. Therefore, PRA Health Sciences's PS Ratio for today is 3.23.
The historical data trend for PRA Health Sciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences Annual Data | |||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 2.21 | 3.00 | 2.32 | 2.66 | 2.73 |
PRA Health Sciences Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
EV-to-Revenue | Get a 7-Day Free Trial | 2.15 | 2.35 | 2.31 | 2.73 | 3.23 |
For the Diagnostics & Research subindustry, PRA Health Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where PRA Health Sciences's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
PRA Health Sciences's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 11472.874 | / | 3333.431 | |
= | 3.44 |
PRA Health Sciences's current Enterprise Value is $11,473 Mil.
PRA Health Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,333 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences (NAS:PRAH) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
PRA Health Sciences's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 165.21 | / | 51.075 | |
= | 3.23 |
PRA Health Sciences's share price for today is $165.21.
PRA Health Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $51.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of PRA Health Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Bonello | officer: EVP & CFO | 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612 |
Shannon Colin | director, officer: President & CEO | PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190 |
Christopher L Gaenzle | officer: EVP, CAO & General Counsel | C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604 |
Glen D. Stettin | director | C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121 |
Alexander George Dickinson | director | 31542 CATALINA AVE LAGUNA BEACH CA 92651 |
Jeffrey T Barber | director | 6501 WESTON PARKWAY, SUITE 200 CARY NC 27513 |
Matthew P. Young | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Linda S Grais | director | 86 ALEJANDRA AVE, ATHERTON CA 94027 |
James C Momtazee | director | 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
George R Roberts | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025 |
Kkr Pra Investors Gp Ii Llc | 10 percent owner | 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
Kkr Pra Investors L.p. | 10 percent owner | 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
Kkr Pra Investors Gp Llc | 10 percent owner | 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 |
Kkr North America Xi Ltd | 10 percent owner | KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
Kkr North America Fund Xi L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 12-18-2020
By PRNewswire PRNewswire • 09-03-2020
By Marketwired Marketwired • 06-18-2020
By Business Wire Business Wire • 04-29-2021
By PRNewswire PRNewswire • 02-27-2021
By Marketwired Marketwired • 03-25-2020
By Marketwired Marketwired • 09-18-2020
By Marketwired Marketwired • 04-14-2020
By Marketwired Marketwired • 02-24-2021
By GuruFocus Research GuruFocus Editor • 05-19-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.